A couple of months back, many countries in the world had started experiencing a slow down in the spread of the coronavirus. As many nations, though inadvertently, lowered the guard, countries across Europe and also the USA saw a resurgence in COVID-19 cases.
Many countries are reporting far more cases every day than they were doing during the first wave. While it remains unclear whether more cases being identified were due to the increase in tests or otherwise, it has certainly put pressure on pharmaceutical companies to expedite the search for an effective vaccine for the virus.
In order to make life get back to normal, we need a vaccine. The vast majority of people are still vulnerable to coronavirus infection. It is only the restrictions on our lives that are preventing more people from dying.
Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. Pharmaceutical companies are starting to unveil medical advances in this battle against the coronavirus.
The massive efforts are indicating that a fast tracked medicine could be available anytime from the end of 2020 to the early months of 2021. As they progress, in the next few weeks, we may learn more about how well these vaccines and treatments work.
Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August. But experts have raised considerable concern about the vaccine’s safety and efficacy is given it has not yet entered Phase 3 clinical trials.
Pfizer/BioNtech is the first pharmaceutical company to share data from the final stages of testing - known as a phase 3 trial. Pfizer believes it will be able to supply 50 million doses by the end of this year, and about 1.3 billion by the end of 2021.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.